Evidence map›Paper›PMID 39535730›Full record

ArticleAngewandte Chemie (International ed. in English)2025

Cationic Metal-Organic Layer Delivers siRNAs to Overcome Radioresistance and Potentiate Cancer Radiotherapy.

Xin Ma, Xiaomin Jiang, Zitong Wang, Yingjie Fan, Jinhong Li, Cathleen Chow, Chaoyu Wang, Chenghua Deng, Wenbin Lin

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Angewandte Chemie (International ed. in English), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Xin MaDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Xiaomin JiangDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Zitong WangDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Yingjie FanDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Jinhong LiDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Cathleen ChowDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Chaoyu WangDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Chenghua DengDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.
Wenbin LinDepartment of Chemistry, The University of Chicago, Chicago, IL 60637, USA.ORCID https://orcid.org/0000-0001-7035-7759

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI MARK W. LINGEN · 1985 to 2026
$122.1M
Nanoscale Metal-Organic Frameworks Enable Radiotherapy-Radiodynamic Therapy and Deliver CpG Oligodeoxynucleotides to Generate Tumor Vaccines and Potentiate Immunotherapy of Head and Neck CancersR01CA253655 · NCI · UNIVERSITY OF CHICAGO · PI LIN, WENBIN, WEICHSELBAUM, RALPH R · 2020 to 2024
$2.5M
NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA253655NIH HHS 1R01CA253655
6 · The paper itself

Abstract

Radiotherapy plays an important role in modern oncology, but its treatment efficacy is limited by the radioresistance of tumor cells. As a member of the inhibitor of apoptosis protein family, survivin plays a key role in developing radioresistance by mediating apoptosis evasion, promoting epithelial-mesenchymal transition, and modulating cell cycle dynamics. Efficient downregulation of survivin expression presents a promising strategy to enhance the antitumor effects of radiotherapy. Herein, we report the design of a hafnium-porphyrin-based cationic metal-organic layer (CMOL) with quaternary ammonium capping groups to deliver small interfering RNAs (siRNAs) for enhanced radiotherapy. The CMOL@siRNA nanoplatform not only increased energy deposition from X-rays and reactive oxygen species generation via a unique radiotherapy-radiodynamic therapy process, but also effectively delivered siRNAs to downregulate survivin expression and ameliorate radioresistance of cancer cells. Consequently, CMOL@siRNA in combination with low-dose X-ray irradiation demonstrated remarkable antitumor efficacy with 96.9 % and 91.4 % tumor growth inhibition in murine colorectal carcinoma and triple-negative breast cancer models, respectively.

Indexed as

Colorectal NeoplasmsMetal-Organic FrameworksRNA, Small InterferingAnimalsApoptosisCationsCell Line, TumorFemaleHumansMiceRadiation ToleranceSurvivinTriple Negative Breast NeoplasmsCationsMetal-Organic FrameworksRNA, Small InterferingSurvivinMetal-organic layersRadioresistanceRadiosensitizersradiotherapysiRNA Delivery

Identifiers

PMID39535730
PMCPMC11811689

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.